Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
for
B-Cell Lymphoma, Myelodysplastic Syndromes (MDS),
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center
Sex: All
Age: 12 - 70+
Code: NCT05092451
Phase1, Phase2, Recruiting
Study of BMS-986453 in Newly Diagnosed Multiple Myeloma
for
Multiple Myeloma
Location: Birmingham AL
Sponsor: Susan Bal
Sex: All
Age: 19+
Code: NCT07333261
Phase1, Recruiting
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
for
Hematologic Malignancies, Inherited Disorders of Metabolism,
Location: Boston MA, New Haven CT, Stony Brook NY, Lake Sucess NY,
Sponsor: Center for International Blood and Marrow Transplant Research
Sex: All
Age: 0+
Code: NCT01351545
Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
Location: Philadelphia PA, Bethesda MD, Atlanta GA,
Sponsor: CellCentric Ltd.
Sex: All
Age: 18+
Code: NCT04068597
Phase1, Phase2, Recruiting
Elranatamab in Relapsed/Refractory Multiple Myeloma
for
Multiple Myeloma
Location: La Jolla CA
Sponsor: University of California, San Diego
Sex: All
Age: 18+
Code: NCT06711705
Phase2, Recruiting
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
for
Multiple Myeloma
Location: Halifax, Boston MA, New Haven CT, Sherbrooke,
Sponsor: European Myeloma Network B.V.
Sex: All
Age: 18+
Code: NCT05243797
Phase3, Recruiting
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
for
Relapsed/Refractory Multiple Myeloma
Location: New York NY, Hackensack NJ, Miami FL, Toronto,
Sponsor: BeOne Medicines
Sex: All
Age: 18+
Code: NCT04973605
Phase1, Phase2, Recruiting
A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications
Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma
for
Multiple Myeloma, Plasma Cell Neoplasm,
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center
Sex: All
Age: 18+
Code: NCT05336383
Phase2, Recruiting
Busulfan, Melphalan, Escalating Carfilzomib Conditioning Auto Stem Cell Transplantation for Multiple Myeloma (MM)
for
Multiple Myeloma
Location: Maywood IL
Sponsor: Loyola University
Sex: All
Age: 18+
Code: NCT03795597
Phase1, Phase2, Recruiting
Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma
for
Multiple Myeloma, Plasma Cell Myeloma
Location: San Francisco CA
Sponsor: Robert Flavell, MD, PhD
Sex: All
Age: 18+
Code: NCT05892393
Phase1, Recruiting
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
for
Multiple Myeloma
Location: Stony Brook NY, Mineola NY, New York NY,